Dr. George Masih, CEO

Dr. George Masih is a recognized authority in peptide technologies, with a career dedicated to advancing drug discovery and vaccine development. With extensive expertise in peptide synthesis, automation, and informatics, George has significantly contributed to the biotechnology and pharmaceutical industries.

 

Before taking on his role at Cambridge Peptides, George was a key figure at Cambridge Antibody Technology (CAT), where he led the Peptide Chemistry department. Joining shortly after CAT’s IPO, he established a high-capacity peptide synthesis facility to support CAT’s internal research and its pharmaceutical and biotechnology partners. Leveraging innovative laboratory automation and informatics, George transformed CAT’s peptide chemistry operations into one of the largest and most efficient in Europe. Beyond his leadership in peptide manufacturing, he played a vital role in multidisciplinary genomics and drug discovery programs at the company.

 

Earlier in his career, George held positions at several leading companies providing peptide and nucleic acid services to the biotechnology and pharmaceutical sectors. He holds a PhD in Chemistry, specializing in peptide-based drug discovery, from the University of Birmingham.

 

With his exceptional expertise and leadership, George continues to drive innovation and excellence in peptide technologies at Cambridge Peptides.